Please login to the form below

Not currently logged in
Email:
Password:

Zevtera

This page shows the latest Zevtera news and features for those working in and with pharma, biotech and healthcare.

Basilea bags $72m upfront from Pfizer for antifungal license

Basilea bags $72m upfront from Pfizer for antifungal license

Basilea launched the antifungal in its first European markets last year - Austria, France, Germany, Italy and the UK - with combined sales of the antifungal and new antibiotic Zevtera (ceftobiprole) reaching ... Meanwhile, Basilea says it is still on the

Latest news

  • Basilea’s novel antibiotic reaches UK market Basilea’s novel antibiotic reaches UK market

    Swiss biopharma company Basilea has launched its new cephalosporin antibiotic Zevtera in the UK, the latest market in its European roll-out for the drug. . ... The launch of Zevtera in Europe is being supported by Quintiles' commercial services unit

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Basilea appoints commercial head Basilea appoints commercial head

    Ronald Scott, CEO of Basilea, commented that Veitch's “extensive experience and in-depth knowledge of European pharmaceutical markets will be instrumental” as the company prepares to launch its antibiotic Zevtera

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics